# OnCo record mogamulizumab-atll-phase-2-japan (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/mogamulizumab-atll-phase-2-japan/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "mogamulizumab-atll-phase-2-japan", "NCT00920790" ;
  schema:name "Mogamulizumab phase 2 in relapsed adult T-cell leukaemia/lymphoma (Japan)"@en ;
  schema:alternateName "KW-0761 phase 2"@en, "Ishida 2012"@en ;
  schema:description "An antibody against CCR4, a protein on the surface of most adult T-cell leukaemia cells, produced a response in half of the people in a Japanese study whose disease had come back after chemotherapy."@en ;
  schema:url <https://onco.cc/trials/mogamulizumab-atll-phase-2-japan/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00920790>, <https://doi.org/10.1200/JCO.2011.37.3472>, <https://doi.org/10.1111/cas.13343> ;
  onco:status "positive" ;
  onco:tag "lymphoma-evidence-entities" ;
  onco:phase "2" ;
  schema:startDate "2009-06" ;
  onco:cancers <https://onco.cc/cancers/adult-t-cell-leukaemia-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/ccr4/> ;
  onco:drugs <https://onco.cc/drugs/mogamulizumab/> ;
  onco:companies <https://onco.cc/companies/kyowa-kirin/> ;
  onco:terms <https://onco.cc/terms/orr/>, <https://onco.cc/terms/lymphoma-htlv-1/> ;
  onco:trials <https://onco.cc/trials/mogamulizumab-atll-0761-009/>, <https://onco.cc/trials/mlsg15-mogamulizumab-atll/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-mogamulizumab-relapsed-atll-phase-2-jco-2012/> .